Piperacillin/tazobactam or ampicillin and gentamicin for empirical treatment of community acquired infection: A randomised clinical trial (PAGER)
When people arrive at hospital with a serious infection, such as pneumonia, a severe kidney infection, or sepsis, doctors must act quickly. They start antibiotics straight away before lab tests confirm the exact bug causing the illness. This trial, called PAGER, compares two well-known antibiotic routines used in hospitals: piperacillin with tazobactam, versus a combination of ampicillin and gentamicin. Both options are already approved and regularly used in the NHS. The researchers want to discover if one choice is better than the other at saving lives and protecting kidney health. Patients admitted to hospital with a suspected serious infection are randomly chosen by a computer to receive one of the two antibiotic treatments through a drip. Doctors track each patient's progress over 30 days to measure recovery and watch for side effects.
At a glance
What is this study about?
When a severe infection strikes, every hour counts. Conditions like sepsis, chest infections, and severe urinary tract infections can make people very unwell very quickly. Because lab tests can take a couple of days to identify the exact germ, hospital doctors start treatment immediately using broad-acting antibiotics. This approach is known as 'empirical treatment'.
Currently, hospital teams tend to rely on two common antibiotic choices. One option is a single medicine called piperacillin/tazobactam. The other is a pair of antibiotics given together, called ampicillin and gentamicin. Both treatments are trusted and have been used for many years, but doctors still debate which one is best to start with.
This clinical trial aims to settle that debate. By directly comparing the two treatments in a large group of hospital patients, researchers hope to see which option leads to higher survival rates and fewer complications, particularly kidney problems. The findings will help hospitals choose the safest, most effective first-choice medicine for patients fighting serious infections in the future.
Key takeaways
- The trial compares two standard, widely used antibiotic treatments for serious infections.
- It involves adults admitted to hospital with conditions like pneumonia, severe urinary infections, or sepsis.
- Patients are randomly assigned to one of two approved antibiotic routines given through a drip.
- Doctors will track recovery and kidney health over a 30-day period.
- Participation is voluntary, and taking part will not change the high standard of hospital care you receive.
Who may be eligible?
This trial is designed for adults aged 18 and older who are admitted to hospital with a serious infection that started in the community (outside of a hospital). This includes conditions such as severe urine or kidney infections, pneumonia, infections of unknown origin, and sepsis.
To be considered, patients must need prompt intravenous antibiotics (medicines given directly into a vein). People who have known severe allergies to penicillin or any of the study medicines, or those who have specific medical reasons why one of the drugs cannot be used, will not be able to join.
Because this treatment must start urgently upon arriving at hospital, the medical team will assess eligibility quickly. If a patient is too unwell to give consent straight away, study rules allow doctors to speak with family members or use approved emergency consent procedures.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- You are aged 18 or older.
- You have been admitted to hospital with a serious infection (such as sepsis, pneumonia, or a kidney infection).
- Your doctors have decided you need intravenous antibiotics immediately.
- Your infection started in the community, not while you were already staying in hospital.
- You do not have a known severe allergy to penicillin or the trial antibiotics.
What does participation involve?
Taking part in this study happens entirely while you are in hospital, with follow-up tracking your health for 30 days. If you join, a computer will assign you at random to receive either piperacillin/tazobactam or the ampicillin and gentamicin combination. Neither you nor your doctor chooses which group you are in, ensuring a fair test.
You will receive your antibiotics through a drip into a vein, which is standard practice for severe infections. The medical team will care for you normally, carrying out routine blood tests to check how well your body is fighting the infection and to monitor your kidney function. Once you finish your course of antibiotics and leave hospital, the research team will check your medical records around day 30 to see how well you have recovered. You will not usually need extra hospital visits outside your standard NHS care.
Potential risks and benefits
Locations (1)
- —UnverifiedDenmark
Common questions
Are these new or experimental medicines?
No. Both treatments are well-established antibiotics that have been used safely in NHS hospitals for many years.
Will anyone receive a placebo (dummy drug)?
No. Everyone in the trial receives active, powerful antibiotics designed to treat their infection.
Why are researchers checking kidney function?
Certain antibiotics can sometimes put temporary stress on the kidneys. The study tracks blood tests over 30 days to see which treatment is gentler on the kidneys.
Will I have to stay in hospital longer if I take part?
No. You will be discharged as soon as your medical team decides you are well enough to go home, exactly as normal.
What happens if the assigned antibiotic does not work?
Your doctors will review your lab results and your recovery daily. If your infection needs a different medicine, they will change your treatment immediately.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.